MOEXA

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 30 Dec 2025 filing date already counts against anyone who files later.

Record

Serial number

99572306

Mark type

Word mark

Filed

30 Dec 2025

Published for opposition

01 Sept 2026

Attorney of record

Joseph G. Chu

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer and fibrosis; Pharmaceutical preparations for medical purposes, namely, for treatment and prevention of lung cancer, colorectal cancer, lymph node cancer, bone cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, liver cancer, prostate cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis, post-viral fibrosis, post coronavirus fibrosis, cystic fibrosis or fibrosis resulting from radiation, renal fibrosis, cardiac fibrosis, liver fibrosis, arthrofibrosis, nephrogenic systemic fibrosis, retroperitoneal fibrosis, scleroderma/systemic sclerosis, myelofibrosis or mediastinal fibrosis, fibrosis associated with arterial stiffness, Crohn's disease, Dupuytren's contracture, keloids, Peyronie's disease or adhesive capsulitis, and inflammation of the body of a human subject; Medical preparations for the treatment of cancer and fibrosis; Veterinary pharmaceutical preparations for the treatment of cancer and fibrosis; Medicaments for the treatment and prevention of cancer and fibrosis; Anti-cancer preparations; Medicaments for the treatment of cancer; Diagnostic agents, preparations and substances for medical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment, inhibition or prevention of cell proliferation; chemical preparations and medicaments for pharmaceutical or medical purposes, namely, for treatment, inhibition or prevention of cancer and fibrosis; Veterinary pharmaceutical preparations for the prevention of cancer and fibrosis; Pharmaceutical preparations for the prevention of cell proliferation; Pharmaceutical preparations for the prevention of cancer; Pharmaceutical preparations for the prevention of fibrosis; Medicaments for the prevention of fibrosis; Dietetic foods adapted for medical use; Dietetic foods adapted for medical purposes; Dietetic pet foods adapted for veterinary use; Dietetic pet foods adapted for veterinary purposes; Dietary supplements for humans and animals; Pharmaceutical preparations for treatment, inhibition or prevention of cancer and fibrosis; Medicaments for treatment, inhibition or prevention of cancer and fibrosis; Medicaments for the prevention of cell proliferation; Medicaments for the prevention of cancer

Owner

• Moexa Pharmaceuticals Limited, Shek Mun, HK
• Moexa Pharmaceuticals Limited, Shek Mun, HK

Prosecution history

• 01 Sept 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 01 Sept 2026 — PUBLISHED FOR OPPOSITION
• 26 Aug 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 05 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 04 Aug 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 03 Aug 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 03 Aug 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 07 May 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 07 May 2026 — NON-FINAL ACTION E-MAILED
• 07 May 2026 — NON-FINAL ACTION WRITTEN
• 29 Apr 2026 — ASSIGNED TO EXAMINER
• 30 Dec 2025 — APPLICATION FILING RECEIPT MAILED
• 30 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 30 Dec 2025 — NEW APPLICATION ENTERED